Axsome Therapeutics Dividend
Dividend criteria checks 0/6
Axsome Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.3% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$6.24 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years
Mar 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AXSM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXSM's dividend payments have been increasing.
Dividend Yield vs Market
| Axsome Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AXSM) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.6% |
| Industry Average (Pharmaceuticals) | 2.3% |
| Analyst forecast in 3 Years (AXSM) | 0% |
Notable Dividend: Unable to evaluate AXSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AXSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AXSM's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AXSM has not reported any payouts.